The European League Against Rheumatism, EULAR, has published recommendations for the management of patients with Sjögren’s syndrome with topical and systemic therapies.
The therapeutic management of Sjögren’s syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this, EULAR supported an international task force to develop evidence-based and consensus-based recommendations for the management of patients with SjS with topical and systemic medications.
The task force developed three overarching principles and 12 specific recommendations for management of SjS. The recommendations form a logical sequence, starting with the management of the central triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic disease.
The three overarching principles are:
- Patients with SjS should be managed at, or in close collaboration with, centres of expertise using a multidisciplinary approach.
- The first therapeutic approach to dryness should be symptomatic relief using topical therapies.
- Systemic therapies may be considered for the treatment of active systemic disease.
The 12 specific recommendations are:
Source: Read Full Article